310 related articles for article (PubMed ID: 16497969)
21. Genetic analysis and clinical picture of severe congenital neutropenia in Israel.
Lebel A; Yacobovich J; Krasnov T; Koren A; Levin C; Kaplinsky C; Ravel-Vilk S; Laor R; Attias D; Ben Barak A; Shtager D; Stein J; Kuperman A; Miskin H; Dgany O; Giri N; Alter BP; Tamary H
Pediatr Blood Cancer; 2015 Jan; 62(1):103-8. PubMed ID: 25284454
[TBL] [Abstract][Full Text] [Related]
22. [Long-term treatment with recombinant human granulocyte colony stimulating factor in patients with severe congenital neutropenia].
Zeidler C; Reiter A; Yakisan E; Koci B; Riehm H; Welte K
Klin Padiatr; 1993; 205(4):264-71. PubMed ID: 7690865
[TBL] [Abstract][Full Text] [Related]
23. Severe congenital neutropenia: abnormal growth and differentiation of myeloid progenitors to granulocyte colony-stimulating factor (G-CSF) but normal response to G-CSF plus stem cell factor.
Hestdal K; Welte K; Lie SO; Keller JR; Ruscetti FW; Abrahamsen TG
Blood; 1993 Nov; 82(10):2991-7. PubMed ID: 7693032
[TBL] [Abstract][Full Text] [Related]
24. Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.
Dale DC; Bolyard AA; Shannon JA; Connelly JA; Link DC; Bonilla MA; Newburger PE
Blood Adv; 2022 Jul; 6(13):3861-3869. PubMed ID: 35476051
[TBL] [Abstract][Full Text] [Related]
25. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia.
Kalra R; Dale D; Freedman M; Bonilla MA; Weinblatt M; Ganser A; Bowman P; Abish S; Priest J; Oseas RS; Olson K; Paderanga D; Shannon K
Blood; 1995 Dec; 86(12):4579-86. PubMed ID: 8541548
[TBL] [Abstract][Full Text] [Related]
26. Increased granulocyte colony-stimulating factor responsiveness but normal resting granulopoiesis in mice carrying a targeted granulocyte colony-stimulating factor receptor mutation derived from a patient with severe congenital neutropenia.
McLemore ML; Poursine-Laurent J; Link DC
J Clin Invest; 1998 Aug; 102(3):483-92. PubMed ID: 9691084
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
Wu L; Li X; Su J; He Q; Zhang X; Chang C; Pu Q
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1563-9. PubMed ID: 21845438
[TBL] [Abstract][Full Text] [Related]
28. G-CSF and its receptor in myeloid malignancy.
Beekman R; Touw IP
Blood; 2010 Jun; 115(25):5131-6. PubMed ID: 20237318
[TBL] [Abstract][Full Text] [Related]
29. Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer.
Danese MD; Schenfeld J; Shaw J; Gawade P; Balasubramanian A; Kelsh M; Hernandez RK; Lyman G
Adv Ther; 2022 Jun; 39(6):2778-2795. PubMed ID: 35430673
[TBL] [Abstract][Full Text] [Related]
30. Game of clones: the genomic evolution of severe congenital neutropenia.
Touw IP
Hematology Am Soc Hematol Educ Program; 2015; 2015():1-7. PubMed ID: 26637693
[TBL] [Abstract][Full Text] [Related]
31. Severe congenital neutropenia.
Welte K; Zeidler C; Dale DC
Semin Hematol; 2006 Jul; 43(3):189-95. PubMed ID: 16822461
[TBL] [Abstract][Full Text] [Related]
32. Impaired myelopoiesis in congenital neutropenia: insights into clonal and malignant hematopoiesis.
Warren JT; Link DC
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):514-520. PubMed ID: 34889405
[TBL] [Abstract][Full Text] [Related]
33. Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia.
Freedman MH
Curr Opin Hematol; 1997 May; 4(3):217-24. PubMed ID: 9209840
[TBL] [Abstract][Full Text] [Related]
34. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
[TBL] [Abstract][Full Text] [Related]
35. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Estey EH; Thall PF; Pierce S; Cortes J; Beran M; Kantarjian H; Keating MJ; Andreeff M; Freireich E
Blood; 1999 Apr; 93(8):2478-84. PubMed ID: 10194425
[TBL] [Abstract][Full Text] [Related]
37. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
38. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
[TBL] [Abstract][Full Text] [Related]
39. The promise of novel treatments for severe chronic neutropenia.
Dale DC; Bolyard AA; Makaryan V
Expert Rev Hematol; 2023; 16(12):1025-1033. PubMed ID: 37978893
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes of myeloid growth factor treatment.
Lyman GH; Dale DC
J Natl Compr Canc Netw; 2011 Aug; 9(8):945-52. PubMed ID: 21900223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
